克唑替尼联合PC方案治疗非小细胞肺癌的临床研究

目的 探讨克唑替尼联合PC方案治疗非小细胞肺癌的临床疗效。方法 选择2016年1月—2018年12月新疆喀什地区第二人民医院治疗的64例非小细胞肺癌患者作为研究对象。用抽签法随机将患者分为对照组和观察组，每组各32例。对照组每天静脉滴入注射用培美曲塞二钠，500 mg/m²，静滴时间超过10 min，并静脉滴入卡铂注射液，AUC5静滴时间超过30 min。观察组在对照组的基础上口服克唑替尼胶囊，250 mg/次，2次/d。1个周期为21 d，两组共治疗2个周期。观察两组患者的临床疗效，同时比较两组患者治疗前后的血清癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）、人鳞状细胞癌相关抗原（SCCAg）以及细胞角蛋白19片段（Cyfra21-1）水平和Karnofsky功能状态评分量表（KPS）评分情况。结果 治疗后，观察组总有效率为81.25%，明显高于对照组的59.37%（P<0.05）。两组治疗后的NSE、CEA、SCCAg和CYFRA21-1水平均明显降低（P<0.05），且观察组上述肿瘤标志物水平明显低于对照组（P<0.05）。治疗后，观察组的生活质量好转率明显高于对照组，恶化率明显低于对照组（P<0.05）。结论 克唑替尼联合PC方案治疗非小细胞肺癌患者的疗效显著，能明显降低肿瘤标志物水平，提高生活质量。

Clinical study on crizotinib combined with PC regimen in treatment of nonsmall cell lung cancer

Objective To investigate the clinical efficacy of crizotinib combined with PC regimen in treatment of non-small cell lung cancer. Methods A total of 64 patients with non-small cell lung cancer treated in The Second People''s Hospital of Kashgar Region from January 2016 to December 2018 were selected as study subjects. Patients were randomly divided into control group and observation group with 32 patients in each group by lottery. Patients in the control group were iv administered with Pemetrexed Disodium for Injection for more than 10 min, 500 mg/m², and iv administered with AUC5 Carboplatin Injection more than 30 min. Patients in the observation group were po administered with Crizotinib Capsules on the basis of control group, 250 mg/time, twice daily. One cycle was 21 days, and the two groups were treated for 2 cycles. After treatment, the clinical efficacy in two groups was observed, and the serum levels of CEA, NSE, SCCAg, Cyfra21-1, and KPS scores before and after treatment in the two groups were compared. Results After treatment, the total effective rate of the observation group was 81.25%, which was significantly higher than 59.37% of the control group (P<0.05). After treatment, the levels of NSE, CEA, SCCAg, and CYFRA21-1 in two groups were significantly decreased (P<0.05), and the levels of tumor markers in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the improvement rate of quality of life in the observation group was significantly higher than that in the control group, and the deterioration rate was significantly lower than that in the control group (P<0.05). Conclusion Crizotinib combined with PC regimen in treatment of non-small cell lung cancer has a significant effect, which can significantly reduce the level of tumor markers, improve the quality of life.